Kamada Stock News

Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel, May 11, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, today a

Kamada press release (KMDA): Q4 GAAP EPS of -$0.11 misses by $0.10.Revenue of $31.47M (-0.1% Y/Y) beats by $9.56M.

Kamada Ltd.'s (KMDA) CEO Amir London on Q4 2021 Results - Earnings Call Transcript

Kamada (NASDAQ:KMDA) is scheduled to announce Q4 earnings results on Tuesday, March 15th, before market open.The consensus EPS Estimate is -$0.01 and the consensus Revenue Estimate…

Wall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will report sales of $23.37 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kamada’s earnings. The lowest sales estimate is $22.24 million and the highest is $24.50 million. Kamada reported sales of $31.54 million during the same quarter last […]

Equities analysts expect that Kamada Ltd. (NASDAQ:KMDA) will announce $0.02 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kamadas earnings. The highest EPS estimate is $0.04 and the lowest is ($0.01). Kamada reported earnings of $0.04 per share in the same quarter last year, which suggests a []

Wall Street analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post $23.37 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with estimates ranging from $22.24 million to $24.50 million. Kamada posted sales of $31.54 million during the same quarter last year, which would indicate []

Kamada Ltd. (NASDAQ:KMDA) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 546,800 shares, a drop of 21.3% from the October 31st total of 695,200 shares. Based on an average daily volume of 49,200 shares, the days-to-cover ratio is presently 11.1 days. Currently, []

Zacks Investment Research downgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and []

HC Wainwright restated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research note issued to investors on Tuesday, Zacks.com reports. Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Kamada from a sell rating to a hold rating in a research report on Wednesday, October 13th. TheStreet cut [] The post Kamada (NASDAQ:KMDA) Receives Buy Rating from HC Wainwright appeared first on ETF Daily News .

Kamada (NASDAQ:KMDA) issued its earnings results on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a return on equity of 6.73% and a net margin of 10.42%. During the same period last year, the firm posted $0.15 […]

Kamada (NASDAQ:KMDA) released its quarterly earnings data on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a net margin of 10.42% and a return on equity of 6.73%. During the same period in the prior year, the […]